Patents by Inventor Brian Noga

Brian Noga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST
    Publication number: 20240041846
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, compositions thereof, and methods of using them are provided.
    Type: Application
    Filed: October 12, 2023
    Publication date: February 8, 2024
    Inventors: Darrell BAKER, Mark BRUCE, Glenn CRATER, Brian NOGA, Marian THOMAS, Patrick WIRE
  • COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST
    Publication number: 20220047565
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 17, 2022
    Inventors: Darrell BAKER, Mark BRUCE, Glenn CRATER, Brian NOGA, Marian THOMAS, Patrick WIRE
  • Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
    Patent number: 11090294
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: August 17, 2021
    Assignee: Glaxo Group Limited
    Inventors: Darrell Baker, Mark Bruce, Glenn Crater, Brian Noga, Marian Thomas, Patrick Wire
  • COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST
    Publication number: 20200171009
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Applicant: Glaxo Group Limited
    Inventors: Darrell BAKER, Mark BRUCE, Glenn CRATER, Brian NOGA, Marian THOMAS, Patrick WIRE
  • COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST
    Publication number: 20180008582
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Application
    Filed: August 16, 2017
    Publication date: January 11, 2018
    Inventors: Darrell BAKER, Mark Bruce, Glenn Crater, Brian Noga, Marian Thomas, Patrick Wire
  • Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
    Patent number: 9750726
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: September 5, 2017
    Assignee: Glaxo Group Limited
    Inventors: Darrell Baker, Mark Bruce, Glenn Crater, Brian Noga, Marian Thomas, Patrick Wire
  • COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST
    Publication number: 20160095840
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Application
    Filed: December 16, 2015
    Publication date: April 7, 2016
    Inventors: Darrell BAKER, Mark BRUCE, Glenn CRATER, Brian NOGA, Marian THOMAS, Patrick WIRE
  • COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST
    Publication number: 20120309725
    Abstract: Novel combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Application
    Filed: November 29, 2010
    Publication date: December 6, 2012
    Inventors: Darrell Baker, Mark Bruce, Glenn Crater, Brian Noga, Marian Thomas, Patrick Wire
  • Crystalline complexes of fluticasone-2-furoate
    Patent number: 7592329
    Abstract: There is provided a crystalline complex comprising a compound of formula (I) in which the crystal lattice is stabilized by the presence of a guest molecule, characterized in that the crystalline complex is of space group P212121 having unit cell dimensions of about 12.5±1.0 §, 15±1.0 §, and 16.2±1.0 § when determined at either 120K or 150K.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: September 22, 2009
    Assignee: Glaxo Group Limited
    Inventors: Keith Biggadike, Steven John Coote, Andrew Craig, David Malcolm Crowe, Victor Witold Jacewicz, Michael John Millan, Rosalyn Kay Nice, Brian Noga, John Frederick Seager, Andrew Lewis Theophilus
  • Method of chemically stabilizing pharmaceutical formulations with cholesterol
    Publication number: 20060165785
    Abstract: The invention relates to a method of improving the chemical stability of an active ingredient substance in a particulate formulation in chemically reactive environment comprising associating the active ingredient substance with a chemically stabilising amount of cholesterol to form composite particles comprising said active ingredient substance and cholesterol.
    Type: Application
    Filed: January 10, 2006
    Publication date: July 27, 2006
    Inventors: Brian Noga, Mark Sommerville, Michael Taylor, Michiel Van Oort
  • Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
    Publication number: 20050152845
    Abstract: A compound of formula (I) in the form of a substantially amorphous solid, and processes for the production thereof.
    Type: Application
    Filed: February 4, 2003
    Publication date: July 14, 2005
    Inventors: Keith Biggadike, Steven Coote, Brian Noga, Michiel Van Oort
  • Crystalline complexes of fluticasone-2-furoate
    Publication number: 20050043284
    Abstract: There is provided a crystalline complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in that the crystalline complex is of space group P212121 having unit cell dimensions of about 12.5±1.0 ?, 15±1.0 ?, and 16.2±1.0 ? when determined at either 120 K or 150 K.
    Type: Application
    Filed: February 4, 2003
    Publication date: February 24, 2005
    Inventors: Keith Biggadike, Steven Coote, Andrew Craig, David Crowe, Victor Jacewicz, Michael Millan, Rosalyn Nice, Brian Noga, John Seager, Andrew Theophilus